← Back to Clinical Trials
Recruiting NCT05876156

NCT05876156 iMOVE: Virtual Reality PT Versus Traditional PT

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05876156
Status Recruiting
Phase
Sponsor Stanford University
Condition Physical Health
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-06-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 25 Years
Study Type INTERVENTIONAL
Interventions
Virtual Reality Physical TherapyTraditional Physical Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-06-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This pragmatic, crossover, randomized controlled study evaluates the efficacy of virtual reality assisted physical therapy (VRPT) for improving the physical activity of hospitalized children as compared to traditional physical therapy. This is a pilot study that will be used to identify patient populations that can benefit the most from VRPT and estimate this effect for future studies. Patients with a significant neurological condition, major developmental disability, active infection of the face or hand, history of severe motion sickness, history of seizures caused by flashing light or had a major surgery within the last 48 hours will be excluded.

Eligibility Criteria

Inclusion Criteria: * Between age 10-25 years * Diagnosed with cancer * Has an active physical therapy consultation * Anticipated inpatient stay for at least 3-days with the second PT session following between 24-72 hours after the first PT session * Ability to understand and the willingness to personally sign the written Institutional Review Board (IRB) approved informed consent document by Legally Authorized Representative (LAR) if participant \<18 years old or by participant if 18+ * Ability to understand and the willingness to personally sign the written IRB approved informed assent document for patient \<18 years old. Exclusion Criteria: * Legal guardian does not present to obtain consent. * Child with a significant neurological condition, or major developmental disability. * Child with active infection of the face or hand. * A history of severe motion sickness. * A history of seizures caused by flashing light. * Major surgery within the last 48 hours. * Does not speak English (required for surveys) * With visual impairments or any degree of developmental delays * Child on mechanical ventilation or ventilatory support

Contact & Investigator

Central Contact

Thomas Caruso

✉ tjcaruso@stanford.edu

📞 650-723-5728

Principal Investigator

Thomas Caruso

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT05876156 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 25 Years, studying Physical Health. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05876156 currently recruiting?

Yes, NCT05876156 is actively recruiting participants. Contact the research team at tjcaruso@stanford.edu for enrollment information.

Where is the NCT05876156 trial being conducted?

This trial is being conducted at Palo Alto, United States.

Who is sponsoring the NCT05876156 clinical trial?

NCT05876156 is sponsored by Stanford University. The principal investigator is Thomas Caruso at Stanford University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology